Related Experiment Video
Updated: Jul 8, 2026
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Octreotide acetate in dominant cystoid macular dystrophy
B F Hogewind1, G Pieters, C B Hoyng
1University Medical Centre St Radboud, Nijmegen, Gelderland, The Netherlands. b.hogewind@ohk.umcn.nl
European Journal of Ophthalmology
|January 19, 2008
Summary
Octreotide acetate, a somatostatin-analogue, showed promise in treating dominant cystoid macular degeneration (DCMD). This treatment may help stabilize visual acuity and reduce macular edema in DCMD patients.
Area of Science:
- Ophthalmology
- Medical Research
Background:
- Dominant cystoid macular degeneration (DCMD) is an inherited condition causing cystoid macular edema.
- DCMD has a poor visual prognosis with no currently effective treatments.
Purpose of the Study:
- To evaluate the efficacy of octreotide acetate, a somatostatin-analogue, in treating early-stage DCMD.
- To assess the impact of octreotide acetate on visual acuity and macular edema in DCMD patients.
Main Methods:
- Four patients with early DCMD received intramuscular long-acting octreotide acetate (20 mg every 4 weeks for 1 year).
- Ophthalmologic examinations and fluorescein angiography (FA) were conducted before and after treatment.
Main Results:
- Seven of eight treated eyes demonstrated improvement on FA.
- Visual acuity remained stable in the majority of treated eyes.
Conclusions:
- Somatostatin-analogues, such as octreotide acetate, may be a viable treatment option for DCMD.
- This treatment approach may help reduce cystoid edema and prevent vision loss associated with DCMD.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...